Tempus AI signs data deals worth up to $192.5 million with Bristol-Myers Squibb, Pathos AI
Bitget2026/10/23 13:05- Tempus AI announced Oct. 23, 2026, agreements with Bristol-Myers Squibb and Pathos AI worth up to $192.5 million over approximately five years.
- The Oct. 14 oncology data agreement provides $137.5 million in fixed payments from Bristol-Myers Squibb through Dec. 31, 2031.
- Pathos AI’s Oct. 22 neurology agreement provides up to $55 million over five years, including $5 million for record updates.
- Neurology data fees depend on delivery of up to 500,000 patient records at $100 each, targeting 100,000 records annually.
- Bristol-Myers Squibb may terminate the oncology agreement with 12 months’ written notice and payment of a substantial termination fee.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
US stock contracts related to AI cloud computing infrastructure collectively fell over the past 24 hours
Northland: The transaction between Mawell Technology and Lumentum highlights the scarce value of InP devices, benefiting related U.S. concept stocks
Northland Capital Markets has upgraded the ratings of Coherent and Applied Optoelectronics following MaxLinear's acquisition of Lumentum.
Goldman Sachs: Maintains "Buy" rating for EQT Energy (EQT.US); Mountain Resources acquisition has strategic significance
Goldman Sachs maintains a "Buy" rating on EQT Energy with a target price of $62.
Crypto prices
More
